EP Patent

EP3572071A1 — Lyophilized liposomes

Assigned to Jazz Pharmaceuticals Research LLC · Expires 2019-11-27 · 6y expired

What this patent protects

A lyophilized gel-phase liposomal composition is provided which comprises more than one therapeutic and/or diagnostic agent, substantially no internal cryoprotectant, gel-phase liposomes with gel-to-liquid crystalline transition temperatures (Tc) that are at least 25°C, wherein t…

USPTO Abstract

A lyophilized gel-phase liposomal composition is provided which comprises more than one therapeutic and/or diagnostic agent, substantially no internal cryoprotectant, gel-phase liposomes with gel-to-liquid crystalline transition temperatures (Tc) that are at least 25°C, wherein the liposomes are 20 mol% or less cholesterol liposomes that are stabilized with at least 1% of a phosphatidylglycerol (PG) and/or a phosphoinositol (PI), and cryoprotectant external to said liposomes. The lyophilized gel-phase liposomal composition and said composition reconstituted in a suitable pharmaceutical carrier are provided for use in therapy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3572071A1
Jurisdiction
EP
Classification
—
Expires
2019-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Research LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.